Pictet Asset Management Holding SA Sells 21,539 Shares of Hologic, Inc. (NASDAQ:HOLX)

Pictet Asset Management Holding SA reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 306,149 shares of the medical equipment provider's stock after selling 21,539 shares during the quarter. Pictet Asset Management Holding SA owned 0.14% of Hologic worth $22,070,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. General Partner Inc. bought a new stake in Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment boosted its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Remove Ads

Hologic Price Performance

HOLX stock traded up $1.13 during mid-day trading on Thursday, hitting $61.69. The company had a trading volume of 4,596,048 shares, compared to its average volume of 1,821,809. The company has a 50-day moving average price of $64.69 and a 200 day moving average price of $72.88. Hologic, Inc. has a 12-month low of $58.38 and a 12-month high of $84.67. The company has a market capitalization of $13.84 billion, a price-to-earnings ratio of 19.46, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of several research reports. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Raymond James reaffirmed an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. BNP Paribas upgraded Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Hologic has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.